Cargando…
Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance
SIMPLE SUMMARY: Glucose metabolic reprogramming is a process in which cells alter the way that glucose is utilized. In breast cancer, cells can undergo this process to fuel their growth, acquire drug resistance, and become metastatic. Scientists have been studying this process to identify new target...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341343/ https://www.ncbi.nlm.nih.gov/pubmed/37444501 http://dx.doi.org/10.3390/cancers15133390 |
_version_ | 1785072239788425216 |
---|---|
author | Lei, Pan Wang, Wenzhou Sheldon, Marisela Sun, Yutong Yao, Fan Ma, Li |
author_facet | Lei, Pan Wang, Wenzhou Sheldon, Marisela Sun, Yutong Yao, Fan Ma, Li |
author_sort | Lei, Pan |
collection | PubMed |
description | SIMPLE SUMMARY: Glucose metabolic reprogramming is a process in which cells alter the way that glucose is utilized. In breast cancer, cells can undergo this process to fuel their growth, acquire drug resistance, and become metastatic. Scientists have been studying this process to identify new targets for breast cancer treatment. By understanding what enzymes and pathways are involved, researchers may be able to develop drugs that specifically target these pathways, ultimately leading to more effective and less toxic treatments for breast cancer in the future. ABSTRACT: The involvement of glucose metabolic reprogramming in breast cancer progression, metastasis, and therapy resistance has been increasingly appreciated. Studies in recent years have revealed molecular mechanisms by which glucose metabolic reprogramming regulates breast cancer. To date, despite a few metabolism-based drugs being tested in or en route to clinical trials, no drugs targeting glucose metabolism pathways have yet been approved to treat breast cancer. Here, we review the roles and mechanisms of action of glucose metabolic reprogramming in breast cancer progression and drug resistance. In addition, we summarize the currently available metabolic inhibitors targeting glucose metabolism and discuss the challenges and opportunities in targeting this pathway for breast cancer treatment. |
format | Online Article Text |
id | pubmed-10341343 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103413432023-07-14 Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance Lei, Pan Wang, Wenzhou Sheldon, Marisela Sun, Yutong Yao, Fan Ma, Li Cancers (Basel) Review SIMPLE SUMMARY: Glucose metabolic reprogramming is a process in which cells alter the way that glucose is utilized. In breast cancer, cells can undergo this process to fuel their growth, acquire drug resistance, and become metastatic. Scientists have been studying this process to identify new targets for breast cancer treatment. By understanding what enzymes and pathways are involved, researchers may be able to develop drugs that specifically target these pathways, ultimately leading to more effective and less toxic treatments for breast cancer in the future. ABSTRACT: The involvement of glucose metabolic reprogramming in breast cancer progression, metastasis, and therapy resistance has been increasingly appreciated. Studies in recent years have revealed molecular mechanisms by which glucose metabolic reprogramming regulates breast cancer. To date, despite a few metabolism-based drugs being tested in or en route to clinical trials, no drugs targeting glucose metabolism pathways have yet been approved to treat breast cancer. Here, we review the roles and mechanisms of action of glucose metabolic reprogramming in breast cancer progression and drug resistance. In addition, we summarize the currently available metabolic inhibitors targeting glucose metabolism and discuss the challenges and opportunities in targeting this pathway for breast cancer treatment. MDPI 2023-06-28 /pmc/articles/PMC10341343/ /pubmed/37444501 http://dx.doi.org/10.3390/cancers15133390 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lei, Pan Wang, Wenzhou Sheldon, Marisela Sun, Yutong Yao, Fan Ma, Li Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance |
title | Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance |
title_full | Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance |
title_fullStr | Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance |
title_full_unstemmed | Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance |
title_short | Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance |
title_sort | role of glucose metabolic reprogramming in breast cancer progression and drug resistance |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341343/ https://www.ncbi.nlm.nih.gov/pubmed/37444501 http://dx.doi.org/10.3390/cancers15133390 |
work_keys_str_mv | AT leipan roleofglucosemetabolicreprogramminginbreastcancerprogressionanddrugresistance AT wangwenzhou roleofglucosemetabolicreprogramminginbreastcancerprogressionanddrugresistance AT sheldonmarisela roleofglucosemetabolicreprogramminginbreastcancerprogressionanddrugresistance AT sunyutong roleofglucosemetabolicreprogramminginbreastcancerprogressionanddrugresistance AT yaofan roleofglucosemetabolicreprogramminginbreastcancerprogressionanddrugresistance AT mali roleofglucosemetabolicreprogramminginbreastcancerprogressionanddrugresistance |